Orchid Pharma witnessed a sharp decline in its stock price, falling nearly 5% following the release of its fourth-quarter results for FY25. As of 10:11 AM, the shares were trading 4.98% lower at Rs 704.30.
The company reported consolidated revenue of ₹237.5 crore in Q4 FY25, a 9.4% rise from ₹217.1 crore in the same quarter last year.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) declined by 3.3% to ₹28 crore from ₹28.9 crore in the previous year’s quarter. As a result, the EBITDA margin narrowed to 11.8% from 13.3%, indicating pressure on operating efficiency.
Net profit dropped significantly by 32.4%, coming in at ₹22.3 crore compared to ₹33 crore in Q4 FY24.
Orchid Pharma shares opened at ₹704.20 today, matching the day’s low. At the time of writing, the stock touched a high of ₹738.65 during trading. Notably, it remains close to its 52-week low of ₹684.35, a significant drop from its 52-week high of ₹1,997.40.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
